
CPIX
Cumberland Pharmaceuticals Inc
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.455
Open
5.260
VWAP
5.14
Vol
75.89K
Mkt Cap
70.47M
Low
4.710
Amount
390.35K
EV/EBITDA(TTM)
25.71
Total Shares
14.19M
EV
68.21M
EV/OCF(TTM)
12.58
P/S(TTM)
1.83
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2022Q1
FY2021Q4
0.00
-100%
0.000
-100%
12.18M
+18.71%
0.060
+500%
Estimates Revision
Stock Price
Go Down

-2.28%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Cumberland Pharmaceuticals Inc (CPIX.O) is 0.00, compared to its 5-year average forward P/E of 8.21. For a more detailed relative valuation and DCF analysis to assess Cumberland Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
8.21
Current PE
0.00
Overvalued PE
28.72
Undervalued PE
-12.30
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
5.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
25.61
Undervalued EV/EBITDA
-14.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.54
Current PS
0.00
Overvalued PS
1.08
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+37.84%
11.71M
Total Revenue
FY2025Q1
YoY :
-169.12%
1.29M
Operating Profit
FY2025Q1
YoY :
-165.61%
1.25M
Net Income after Tax
FY2025Q1
YoY :
-157.14%
0.08
EPS - Diluted
FY2025Q1
YoY :
-274.62%
3.83M
Free Cash Flow
FY2025Q1
YoY :
+15.88%
79.25
Gross Profit Margin - %
FY2025Q1
YoY :
-1.85%
12.74
FCF Margin - %
FY2025Q1
YoY :
-147.61%
10.66
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CPIX News & Events
Events Timeline
2025-05-13 (ET)
2025-05-13
16:15:45
Cumberland announces partnership with Qureight

2024-12-09 (ET)
2024-12-09
15:17:07
Cumberland announces FDA approves sNDA for Acetadote product

2024-11-27 (ET)
2024-11-27
12:33:32
Cumberland sNDA for Acetadote approved by FDA


Sign Up For More Events
Sign Up For More Events
News
7.5
05-13NewsfilterCUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
9.5
04-29NewsfilterCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
9.0
03-19NewsfilterFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Sign Up For More News
People Also Watch

AAPL
Apple Inc
211.260
USD
-0.09%

TSLA
Tesla Inc
349.980
USD
+2.09%

MSFT
Microsoft Corp
454.270
USD
+0.25%

META
Meta Platforms Inc
640.340
USD
-0.55%

NVDA
NVIDIA Corp
135.400
USD
+0.42%

ORCL
Oracle Corp
160.490
USD
+0.68%

WMT
Walmart Inc
98.240
USD
+1.96%

AVGO
Broadcom Inc
228.610
USD
-1.73%

XOM
Exxon Mobil Corp
108.190
USD
-0.36%

AMZN
Amazon.com Inc
205.590
USD
+0.20%
FAQ

What is Cumberland Pharmaceuticals Inc (CPIX) stock price today?
The current price of CPIX is 4.71 USD — it has decreased -10.11 % in the last trading day.

What is Cumberland Pharmaceuticals Inc (CPIX)'s business?

What is the price predicton of CPIX Stock?

What is Cumberland Pharmaceuticals Inc (CPIX)'s revenue for the last quarter?

What is Cumberland Pharmaceuticals Inc (CPIX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cumberland Pharmaceuticals Inc (CPIX)'s fundamentals?

How many employees does Cumberland Pharmaceuticals Inc (CPIX). have?
